Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05059158 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Study acronym: AmyClearAD
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 2024 to Sep 2025
    • Study completion date: Jun 2024 to Oct 2025
    v4
  2. Primary and study completion dates: Jun 2023 to Jun 2024v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
Trial Details
NCT Number NCT05059158
Lead Sponsor Ludwig-Maximilians - University of Munich
Conditions
(from sponsor)		 Alzheimer's Disease (AD)
Related terms Alzheimer Disease, Cognitive Dysfunction
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov